Back to results
US 10,766,966 B2Granted
CD73 blockade
AssigneeInnate Pharma
InventorsIvan Perrot, Carine Paturel, Laurent Gauthier
Life of this patent
Estimating the term…
Abstract
This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5′ nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.
Claims12
An isolated antibody or antibody fragment that specifically binds a human CD73 polypeptide at the surface of a cell and that is capable of neutralizing the 5′-ectonucleotidase activity thereof, selected from the group consisting of:
- (a) monoclonal antibody or antibody fragment comprising (i) a heavy chain variable region comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
- 3 and (ii) a light chain variable region comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
- 4;
- (b) monoclonal antibody or antibody fragment comprising (i) a heavy chain variable region comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
- 3 and (ii) a light chain variable region comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
- 21;
- (c) monoclonal antibody or antibody fragment comprising (i) a heavy chain variable region comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
- 28 and (ii) a light chain variable region comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
- 29;
- and
- (d) monoclonal antibody or antibody fragment comprising (i) a heavy chain variable region comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
- 36 and (ii) a light chain variable region comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
- 37.
10 more elements
Dependencies are inferred from the claim text.